By: Kya Fawley
Two pharmaceutical companies recently joined forces and invested $300 million in a new plant that will produce inhaled insulin.
Hoechst Marion Roussel (HMR), part of Hoechst AG pharmaceuticals, and Pfizer have already laid the foundation for the insulin plant, located in the Hoechst industrial park in Frankfurt, Germany.
HMR and Pfizer agreed to jointly produce and market an inhaled insulin product in November 1998. Their product is now in phase three of clinical trials.